Cargando…

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer

Optimal treatment for advanced cervical cancer after first line chemotherapy remains undefined. Immune checkpoint inhibition with pembrolizumab, a programmed cell death protein 1(PD-1) inhibitor, is under investigation. We analyzed the micro-environmental and molecular genetic profile of tumors from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngoi, N.Y.L., Heong, V., Lee, X.W., Huang, Y.Q., Thian, Y.L., Choo, B.A., Lim, D., Lim, Y.W., Lim, S.E., Ilancheran, A., Soong, R., Tan, D.S.P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993533/ https://www.ncbi.nlm.nih.gov/pubmed/29892689 http://dx.doi.org/10.1016/j.gore.2018.01.009

Ejemplares similares

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
por: Ngoi, N.Y.L., et al.
Publicado: (2021)

PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report
por: Sachdeva, Manavi, et al.
Publicado: (2021)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Lung Adenocarcinoma with Paraneoplastic Hyper-Eosinophilia Not Responding To Pembrolizumab
por: Wehbe, Hisham, et al.
Publicado: (2021)

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma
por: Lim, Jing Quan, et al.
Publicado: (2020)

Brain metastases from breast cancer may respond to endocrine therapy: report of two cases
por: Wang, Qian, et al.
Publicado: (2019)

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
por: Prasad, Femin, et al.
Publicado: (2023)

Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
por: Park, Jonathan J., et al.
Publicado: (2023)

Masters et al. Respond
por: Masters, Ryan K., et al.
Publicado: (2017)

RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment
por: Siddiqui, Jalal, et al.
Publicado: (2021)

A case of adrenal undifferentiated pleomorphic sarcoma with tertiary lymphoid structures responded to pembrolizumab
por: Kokubun, Hidetoshi, et al.
Publicado: (2023)

Juvenile Hemochromatosis: Rheumatic Manifestations of 2 Sisters Responding to Deferasirox Treatment. A Case Series and Literature Review
por: Alqanatish, Jubran, et al.
Publicado: (2021)

Extensive Discoid Lupus Erythematosus in a HIV patient Responding to Hydroxychloroquine Monotherapy
por: Bhagwat, Pradeep Vittal, et al.
Publicado: (2012)

Neural correlates of delusional infestation responding to aripiprazole monotherapy: a case report
por: Ponson, Laura, et al.
Publicado: (2015)

The authors respond: monkeypox presentations
por: Brady, William J., et al.
Publicado: (2023)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Strain-time curve analysis by speckle tracking echocardiography in cardiac resynchronization therapy: Insight into the pathophysiology of responders vs. non-responders
por: To, Andrew C. Y., et al.
Publicado: (2016)

The Authors Respond
por: Traini, Eugenio, et al.
Publicado: (2022)

The Authors Respond
por: Carlson, Josh J., et al.
Publicado: (2018)

The Authors Respond
por: Touchette, Daniel R., et al.
Publicado: (2020)

To respond or not to respond: exploring empathy-related psychological and structural brain differences between placebo analgesia responders and non-responders
por: Hartmann, Helena, et al.
Publicado: (2023)

Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non‐responders: Subgroup analysis of UNCOVER‐3 trial
por: Rosmarin, D., et al.
Publicado: (2021)

THE AUTHORS RESPOND
por: Roth, Joshua A., et al.
Publicado: (2020)

LATE ONSET CANDIDA KRUSEI SEPTICAEMIA IN A NEONATE WHICH RESPONDED TO FLUCONAZOLE MONOTHERAPY: A CASE REPORT
por: Adigun, M.B., et al.
Publicado: (2022)

Respondent
por: Mitchell, Samuel A.
Publicado: (1992)

Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
por: Sheppard, JD, et al.
Publicado: (2019)

Responding to health inequities: Indigenous health system innovations
por: Lavoie, J. G., et al.
Publicado: (2016)

To respond or not to respond, the recurring question in plant mechanosensitivity
por: Leblanc-Fournier, Nathalie, et al.
Publicado: (2014)

Genetic control of the immune response to myoglobins. Both low and high responder T cells tolerant to the other major histocompatibility complex help high but not low responder B cells
por: Kohno, Y, et al.
Publicado: (1982)

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
por: Lee, Yong Jae, et al.
Publicado: (2021)

Social capital and public health: responding to the COVID-19 pandemic
por: Wong, Anna S. Y., et al.
Publicado: (2020)

Dedifferentiated endometrioid adenocarcinoma of the uterus: A case series and review of literature
por: Goh, C., et al.
Publicado: (2020)

Rainforest trees respond to drought by modifying their hydraulic architecture
por: Tng, David Y. P., et al.
Publicado: (2018)

Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis
por: Tsuji, S, et al.
Publicado: (2012)

Standardizing Scenarios to Assess the Need to Respond to an Influenza Pandemic
por: Meltzer, Martin I., et al.
Publicado: (2015)

Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
por: Thomsen, Kenneth, et al.
Publicado: (2018)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic
por: Jit, Mark, et al.
Publicado: (2021)

Brain regions preferentially responding to transient and iso-intense painful or tactile stimuli
por: Su, Q., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dehko2echpdsvvbd2a5flhqsh5